Sigachi Industries Limited (SIGACHI) Fair Value & Analysis
Healthcare · IN · Market cap ₹8.7B
Fair value as of: Jul 3, 2026
From 8 valuation models · updated today
Share price +5.0% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹16.92 – ₹44.72 · fair‑value band ₹8.37 – ₹16.41 · the ₹22.70 price screens above the ₹12.39 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sigachi Industries Limited (SIGACHI) currently trades at ₹22.70, while our model-based Fair Value estimate is ₹12.39 — implying the stock looks roughly 45.4% overvalued today. We read business quality at 30/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Sigachi Industries Limited generated revenue of ₹4.9B at a net margin of -16.8%. Revenue grew 1.0% year over year. It earns a return on equity of -14.5%. Net debt stands at ₹1.4B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Sigachi Industries Limited manufactures and sells microcrystalline cellulose and cellulose powder in India. The company offers cellulose-based products under the HiCel, AceCel, CoatCel, GloCel, and BARETab names; and various chemicals, including colloidal silicon dioxide, carboxy cellulose sodium and mannitol, etc. to active pharmaceutical ingredients, food and nutrition, cosmetic, and chemical industries. It also provides operations and maintenance services in the fields of speciality chemicals, petrochemicals, water treatment, and pharmaceuticals. In addition, the company exports its products. Sigachi Industries Limited was incorporated in 1989 and is headquartered in Hyderabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Sigachi Industries Limited reported revenue of ₹4.8B in FY2026 versus ₹2.5B in FY2022, a compound +17.5%/yr. Reported net income was −₹818M in FY2026.
Is SIGACHI fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sigachi Industries Limited (SIGACHI) undervalued?
What is the fair value of SIGACHI?
What is the quality score of SIGACHI?
What is the revenue of Sigachi Industries Limited (SIGACHI)?
What is the net profit margin of SIGACHI?
Does Sigachi Industries Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.